{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:00:06Z","timestamp":1790892006628,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:33:40Z","timestamp":1790890420000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Platform Trials for the Treatment of Newly Diagnosed and Recurrent Glioblastoma"],"prefix":"10.1016","author":[{"given":"Deveney","family":"Franklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique M.O.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2026.09.004_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2026.09.004_bib2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1078-0432.CCR-20-3805","article-title":"Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma","volume":"27","author":"Andrews","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.09.004_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.09.004_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.09.004_bib5","unstructured":"CBTRUS. Glioblastoma Factsheet: United States 2017\u20132021. Central Brain Tumor Registry of the United States."},{"key":"10.1016\/j.hoc.2026.09.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110373","article-title":"Broad applicability of the goldspire\u2122 platform for the treatment of solid tumors","volume":"268","author":"Zilberberg","year":"2024","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.004_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/fon-2023-0702","article-title":"Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients","volume":"20","author":"Lee","year":"2024","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.004_bib8","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2001.19.8.2189","article-title":"Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas","volume":"19","author":"Andrews","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.004_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/cns.14.54","article-title":"Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax\u00ae platform in the treatment of glioblastoma multiforme","volume":"4","author":"Hdeib","year":"2015","journal-title":"CNS Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.004_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2026.09.004_bib11","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2026.09.004_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.004_bib13","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2026.09.004_bib14","unstructured":"Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc. Clinicaltrials.Gov, Available at: https:\/\/clinicaltrials.gov\/study\/NCT05366179 (Accessed 16 August 2026)."},{"issue":"1","key":"10.1016\/j.hoc.2026.09.004_bib16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2026.09.004_bib17","unstructured":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM (SONOBIRD).\u201d Clinicaltrials.Gov, clinicaltrials.gov\/study\/NCT05902169. Accessed August 16, 2026."}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:33:42Z","timestamp":1790890422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"alternative-id":["S0889858826001140"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Platform Trials for the Treatment of Newly Diagnosed and Recurrent Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}